Sanofi’s MS Drug Takes Double Hit With FDA Delay, Trial Failure
Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial.
By Ashleigh Furlong · Bloomberg
Sanofi’s experimental multiple sclerosis drug got hit with two setbacks on Monday: a regulatory delay in the US as well as a failure in a late-stage clinical trial.